Trials / Completed
CompletedNCT02338856
Safety, Tolerability and Pharmacokinetic Study of MB12066 in Healthy Male Volunteers
A Phase I Clinical Trial to Evaluate the Pharmacokinetics and Safety of MB12066 in Healthy Male Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 11 (actual)
- Sponsor
- Yungjin Pharm. Co., Ltd. · Industry
- Sex
- Male
- Age
- 20 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to investigate the safety and tolerability of MB12066 after multiple dose and to investigate the pharmacokinetic characteristics of MB12066 after multiple dose.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MB12066 200mg | 100mg bid (multiple dose, day 8) |
| DRUG | Placebo | 100mg bid (multiple dose, day 8) |
Timeline
- Start date
- 2015-01-01
- Primary completion
- 2015-02-01
- Completion
- 2015-02-01
- First posted
- 2015-01-14
- Last updated
- 2017-12-21
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT02338856. Inclusion in this directory is not an endorsement.